Study Endorses Benefits of Population-Based BRCA Screening
Implementing population-based BRCA1/2 testing is not only cost-effective in high- and upper middle–income countries but could also prevent tens of thousands of breast and ovarian cancer cases compared with the current clinical strategy, which recommends testing only for high-risk women.
Investigators Untangle Emerging Strategies in Gastric Cancer
Findings from clinical trials evaluating HER2-directed and immunotherapeutic approaches for treating patients with gastric cancer are among recent data attracting interest from experts in the gastrointestinal cancer field.
Community Practice Provides Model for Finding New Revenue in COVID-19 Era
The coronavirus disease 2019 pandemic is highlighting how independent community oncology practices are the best source for patients to receive care close to home, while also presenting several challenges for practices and their patients.
Pemigatinib Trial Seeks to Build on Targeted Advances in Cholangiocarcinoma
An explosion of research in the field led to the approval of pemigatinib in April 2020 for patients with unresectable, previously treated advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement.
Investigator Looks to Novel Therapy to Advance TP53-Mutant MDS Landscape
David P. Steensma, MD, discusses the importance of evaluating eprenetapopt in the pivotal phase 3 study, the agent’s potential role in the MDS landscape, and some of the questions that remain in this setting.
New Options Mark Major Strides in Treating HER2+ Metastatic Breast Cancer
A panel of breast cancer experts discuss a variety of new and emerging agents to
treat patients with advanced or metastatic HER2-positive breast cancer with disease
progression following treatment with at least 1 anti-HER2 therapy.
Relapsed/Refractory DLBCL Paradigm Gains Chemotherapy-Free Option
Kami J. Maddocks, MD, discusses the tolerability and promise of tafasitamab in combination with lenalidomide in relapsed or refractory DLBCL.
Interest Builds for Targeting TIGIT Checkpoint
TIGIT, an inhibitory immune checkpoint that plays a central role in limiting antitumor responses, is attracting robust interest in the research community as a novel target for combination therapies across a range of cancer types, particularly solid tumors.
Traina Helps Navigate Surge of New Breast Cancer Therapies
Nearly 15 years have passed since pathologists at Memorial Sloan Kettering Cancer Center conducted gene expression analyses on breast cancer primary tumors and described a potential role for a novel target, which quickly became a major research focus for their colleague Tiffany A. Traina, MD.
Scramble Over COVID-19 Clinical Trials Holds Lessons for Oncology
Because it is likely that COVID-19 will be around for a considerable period of time, it is hoped that all involved in the clinical research establishment can view this experience as a process that needs substantial improvement.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.